This review summarizes the advances in Hepatitis E virus vaccine development, highlighting Hecolin as the only currently licensed vaccine.
Answers are grounded in this paper and cite their sources.
Hecolin remains sole licensed HEV vaccine; leaves open global approval and further candidates.
Hepatitis E virus (HEV) infection is an emerging zoonotic disease posing a severe threat to public health in the world, especially to pregnant women. Currently, no specific treatments are available for HEV infection. Therefore, it is crucial to develop vaccine to prevent this infection. Although several potential candidate vaccines against HEV have been studied for their immunogenicity and efficacy, only Hecolin® which is developed by Xiamen Innovax Biotech Co., Ltd. and approved by China Food and Drug Administration (CFDA) in 2012, is the licensed HEV vaccine in the world so far. Extensive studies on safety, immunogenicity and efficacy in phase III clinical trials have shown that Hecolin® is a promising vaccine for HEV prevention and control. In this article, the advances on HEV vaccine development and research are briefly reviewed.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: